Article Type
Changed
Tue, 08/02/2022 - 19:17

Key clinical point: Abatacept significantly improved disease activity compared with tumor necrosis factor inhibitors (TNFi) in a real-world population of patients with established anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA).

 

Major finding: At 1-year, the mean change in clinical disease activity index (CDAI) score was significantly higher with abatacept vs TNFi (16.78 vs 13.61; P  =  .020), with a higher proportion of patients receiving abatacept vs TNFi achieving CDAI remission or low disease activity (68% vs 52.6%; P  =  .013).

 

Study details: The data come from an observational cohort study that propensity-score matched 291 patients with ACPA-positive RA who initiated abatacept (n = 97) or TNFi (n = 194).

 

Disclosures: This study was sponsored by Bristol-Myers Squibb. The authors declared no conflicts of interest.

 

Source: Kim MJ, Lee S-K, et al. Efficacy of abatacept versus tumor necrosis factor inhibitors in anti-citrullinated protein antibody-positive patients with rheumatoid arthritis: Results from a Korean nationwide biologics registry. Rheumatol Ther. 2022 (Jun 18). Doi: 10.1007/s40744-022-00467-4

Publications
Topics
Sections

Key clinical point: Abatacept significantly improved disease activity compared with tumor necrosis factor inhibitors (TNFi) in a real-world population of patients with established anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA).

 

Major finding: At 1-year, the mean change in clinical disease activity index (CDAI) score was significantly higher with abatacept vs TNFi (16.78 vs 13.61; P  =  .020), with a higher proportion of patients receiving abatacept vs TNFi achieving CDAI remission or low disease activity (68% vs 52.6%; P  =  .013).

 

Study details: The data come from an observational cohort study that propensity-score matched 291 patients with ACPA-positive RA who initiated abatacept (n = 97) or TNFi (n = 194).

 

Disclosures: This study was sponsored by Bristol-Myers Squibb. The authors declared no conflicts of interest.

 

Source: Kim MJ, Lee S-K, et al. Efficacy of abatacept versus tumor necrosis factor inhibitors in anti-citrullinated protein antibody-positive patients with rheumatoid arthritis: Results from a Korean nationwide biologics registry. Rheumatol Ther. 2022 (Jun 18). Doi: 10.1007/s40744-022-00467-4

Key clinical point: Abatacept significantly improved disease activity compared with tumor necrosis factor inhibitors (TNFi) in a real-world population of patients with established anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA).

 

Major finding: At 1-year, the mean change in clinical disease activity index (CDAI) score was significantly higher with abatacept vs TNFi (16.78 vs 13.61; P  =  .020), with a higher proportion of patients receiving abatacept vs TNFi achieving CDAI remission or low disease activity (68% vs 52.6%; P  =  .013).

 

Study details: The data come from an observational cohort study that propensity-score matched 291 patients with ACPA-positive RA who initiated abatacept (n = 97) or TNFi (n = 194).

 

Disclosures: This study was sponsored by Bristol-Myers Squibb. The authors declared no conflicts of interest.

 

Source: Kim MJ, Lee S-K, et al. Efficacy of abatacept versus tumor necrosis factor inhibitors in anti-citrullinated protein antibody-positive patients with rheumatoid arthritis: Results from a Korean nationwide biologics registry. Rheumatol Ther. 2022 (Jun 18). Doi: 10.1007/s40744-022-00467-4

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Rheumatoid Arthritis, August 2022
Gate On Date
Tue, 05/24/2022 - 16:15
Un-Gate On Date
Tue, 05/24/2022 - 16:15
Use ProPublica
CFC Schedule Remove Status
Tue, 05/24/2022 - 16:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article